BETA
Your AI-Trained Oncology Knowledge Connection!
I-DXd Shows “Impressive” Responses in Extensive-Stage SCLC
Data from the IDeate-Lung01 trial support the potential role that ifinatamab deruxtecan may play in the management of extensive-stage small cell lung cancer.
Lurbinectedin Yields Responses in Various ES-SCLC Subgroups
Lurbinectedin achieved an ORR of 27% in all patients with extensive-stage small cell lung cancer in the phase 4 Jazz EMERGE 402 study.
Ateganosine Combo Exhibits Favorable Efficacy vs SOC in Advanced NSCLC
Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.
WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care
Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.
Surufatinib Combo Displays Promising Efficacy in Frontline ES-SCLC
All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.
SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC
No new safety signals were identified with subcutaneous amivantamab in EGFR-mutant NSCLC, and infusion reactions were reduced vs the IV formulation.
Vobramitamab Duocarmazine Does Not Achieve Responses in R/R ES-SCLC
After failing to record any objective responses in 9 patients with relapsed/refractory ES-SCLC, the phase 2 trial was terminated early.
Tarlatamab Remains Safe and Effective in Extensive-Stage SCLC
Results from the DeLLphi-303 trial showed sustained efficacy and safety with tarlatamab plus anti–PD-1 treatment for patients with extensive-stage SCLC.
ABBV-706 Demonstrates Tumor Shrinkage, Tolerability in Pretreated R/R SCLC
The confirmed overall response rate with ABB-706 was 77% in patients with relapsed/refractory small cell lung cancer who received 2 prior lines of therapy.
Crizotinib Falls Short on DFS and OS Improvements in ALK+ NSCLC
When compared with observation, adjuvant crizotinib did not improve disease-free survival or overall survival in ALK-positive NSCLC.
Frontline Aumolertinib/Chemo Yields PFS Superiority in EGFR+ NSCLC
Adding aumolertinib to chemotherapy in the treatment of patients with EGFR-mutated NSCLC led to improvements in progression-free survival.
Dato-DXd Increases Intracranial Responses/PFS in NSCLC With Brain Mets
The median CNS PFS with Dato-DXd was 5.0 months vs 3.0 months with docetaxel in patients with NSCLC who have brain metastases.
Concurrent Durvalumab Plus Chemo/RT Does Not Improve Efficacy in Stage III NSCLC
For patients with unresectable stage III NSCLC, concurrent durvalumab with chemotherapy/radiation did not show an efficacy improvement.
Adjuvant Nivolumab/Chemo Reduces Recurrence Risk in Resected NSCLC
The safety and tolerability of nivolumab/chemotherapy in non–small cell lung cancer were manageable and consistent with its profiles in other clinical scenarios.
Zidesamtinib Exhibits Durable Activity in Pretreated ROS1+ Advanced NSCLC
Zidesamtinib was well tolerated in patients who received prior ROS1 TKI therapy with advanced NSCLC, and dose discontinuation/reduction rates were low.
Ivonescimab/Chemo After TKI Progression Improves PFS in EGFR-Mutated NSCLC
Ivonescimab plus chemotherapy following progression after a third-generation TKI showed consistent efficacy across EGFR-mutated NSCLC subgroups.
Perioperative Pembrolizumab Combo Improves Responses in NSCLC Subgroups
Subgroup data from KEYNOTE-671 support the use of perioperative pembrolizumab in stage II or III non–small cell lung cancer of any clinical nodal status.
Osimertinib Combo Exhibits OS Improvement in EGFR-Mutated Advanced NSCLC
AE-related discontinuations of osimertinib were low, and no new treatment-related deaths were reported with the combination in EGFR-mutant NSCLC.
Neoadjuvant/Adjuvant Durvalumab Combo Elicits Sustained EFS in NSCLC
Updated findings from the AEGEAN trial support perioperative durvalumab as a new therapy option for those with resectable non–small cell lung cancer.
Taletrectinib Yields Intracranial Responses in Advanced ROS1+ NSCLC
Phase 2 data show meaningful efficacy with taletrectinib regardless of whether patients with ROS1-positive NSCLC previously received tyrosine kinase inhibitors.
Firmonertinib Yields Responses in EGFR-Mutant NSCLC Subtype
Confirmed partial responses with firmonertinib occurred across a range of EGFR PACC mutations among patients with NSCLC in the phase 1b FURTHER trial.
Amivantamab Combo Reduces Symptom Progression in EGFR-Mutated NSCLC
Patients with EGFR-mutated NSCLC had sustained HRQOL when treated with amivantamab plus lazertinib vs osimertinib.
Ivonescimab Improves PFS Vs Pembrolizumab in Advanced PD-L1+ NSCLC
Data from the HARMONi-2 trial support the potential superiority of frontline ivonescimab vs pembrolizumab in non–small cell lung cancer.
NeoCOAST-2 Data Show Pathologic Responses Across Various Combos in NSCLC
In particular, dato-DXd plus durvalumab and chemotherapy produced the highest pCR and mPR rates in the phase 2 NeoCOAST-2 trial.
Zongertinib Yields Meaningful Responses in Pretreated HER2-Mutated NSCLC
Phase 1b data also show encouraging preliminary intracranial activity with zongertinib among patients with HER2-mutant non–small cell lung cancer.
Novel TKI Exhibits Durable Responses in HER2-Mutated NSCLC
BAY 2927088 showed substantial response rates for patients with pretreated HER2-mutant non–small cell lung cancer.
Amivantamab Combo Shows Improved OS Trend Vs Osimertinib in EGFR+ NSCLC
Amivantamab/lazertinib also reduces the risk of second progression or death compared with osimertinib in the phase 3 MARIPOSA trial.
Deep Learning Models Expedite Biomarker Discovery, Detection in Lung Cancer
Investigators showcased feasibility of combining pathology findings with deep learning artificial intelligence to speed up biomarker detection and discovery for patients with lung cancer.
SHP2/KRAS Inhibitor Combo Yields Activity in KRAS G12C+ Solid Tumors
Investigators of the phase 1b/2 KontRASt-01 trial will continue their evaluation of TNO155 plus JDQ433 in KRAS G12C-mutated solid tumors as part of an expansion portion of the trial.
Zongertinib Yields Activity, Acceptable Safety in HER2-Mutated NSCLC
Treatment with zongertinib produces low rates of EGFR-mediated adverse effects among patients with HER2-mutated non–small cell lung cancer in the phase 1a/b BEAMION Lung-1 trial.
